Last --
Change Today 0.00 / 0.00%
Volume 0.0
858 On Other Exchanges
Symbol
Exchange
858 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

extrawell pharmaceutical (858) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for EXTRAWELL PHARMACEUTICAL (858)

Related News

No related news articles were found.

extrawell pharmaceutical (858) Related Businessweek News

No Related Businessweek News Found

extrawell pharmaceutical (858) Details

Extrawell Pharmaceutical Holdings Limited, an investment holding company, engages in the development, manufacture, and sale of pharmaceutical products in the People’s Republic of China. The company operates through Manufacturing, Trading, Gene development, and Oral Insulin segments. It offers Transfer Factor Oral Solution, a dual immune regulator for the treatment of diseases caused by virus infection and weak cellular immune system; and Wisk for the treatment of II-III degree of radio-injury of skin, normal common burn, actinic dermatitis, various infectious ulcers, and oral ulcers, as well as for trauma and post operation wound healing. The company also provides ZhouBang, a thromboxane synthetase inhibitor to prevent the coagulation of platelets and facilitate relaxation of blood vessels; Feining Pian, which is used for the treatment of chronic cough, acute upper respiratory tract infection, infection associated with bronchitis, and emphysema; and YouHuanPing, a sustained-release tablet for sideropenic anemia. It is also involved in the marketing and distribution of imported pharmaceutical products consisting of GM-1 to treat lesions of central nervous system due to vascular or traumatic events and Parkinson's disease; Millibar for the treatment of high blood pressure; and Skin-Cap for use in the treatment of psoriasis, dandruff, dermatitis, atopic dermatitis, eczema, and tinea. In addition, the company engages in the commercial exploitation and development of genome-related technology; development and commercialization of oral insulin products; and provision of agency services. Further, it engages in property investment business. Extrawell Pharmaceutical Holdings Limited is headquartered in Quarry Bay, Hong Kong.

312 Employees
Last Reported Date: 07/29/14

extrawell pharmaceutical (858) Top Compensated Officers

Chairman, Chief Executive Officer, Chairman o...
Total Annual Compensation: $1.1M
Honorary Chairman and Chief Scientific Adviso...
Total Annual Compensation: $340.0K
Qualified Accountant, Financial Controller, J...
Total Annual Compensation: $275.0K
Executive Director
Total Annual Compensation: $363.0K
Executive Director
Total Annual Compensation: $148.0K
Compensation as of Fiscal Year 2014.

extrawell pharmaceutical (858) Key Developments

Extrawell Pharmaceutical Holdings Ltd., Annual General Meeting, Aug 29, 2014

Extrawell Pharmaceutical Holdings Ltd., Annual General Meeting, Aug 29, 2014., at 15:00 China Standard Time. Location: Monaco Room, Basement 1, Regal Hongkong Hotel. Agenda: To receive and consider the audited consolidated financial statements and the reports of the directors and the independent auditors of the company for the year ended 31 March 2014; to re-elect retiring directors and to authorize the board of directors of the company to fix the directors' remuneration; to re-appoint the independent auditors and to authorize the board of directors of the company to fix their remuneration; and to authorise the directors to allot, issue and deal with the unissued shares of HKD 0.01 each in the capital of the Company and to make or grant offers, agreements and options, including warrants to subscribe for Shares.

Extrawell Pharmaceutical Holdings Ltd. Reports Audited Consolidated Earnings Results for the Year Ended March 31, 2014

Extrawell Pharmaceutical Holdings Ltd. reported audited consolidated earnings results for the year ended March 31, 2014. For the year, the company's turnover was HKD 150,673,000 compared to HKD 151,068,000 for the same period of last year. Profit from operations was HKD 37,789,000 compared to HKD 8,886,000 for the same period of last year. Profit before taxation was HKD 30,896,000 compared to HKD 8,886,000 for the same period of last year. Profit for the year attributable to equity holders of the company was HKD 15,700,000 or 0.67 cents per basic share compared to HKD 10,876,000 or 0.47 cents per basic share for the same period of last year. Net cash generated from operating activities was HKD 82,330,000 compared with HKD 10,414,000 for the same period last year. Purchases of property, plant and equipment was HKD 139,266,000 compared with HKD 31,170,000 for the same period last year.

Extrawell Pharmaceutical Holdings Ltd., Special/Extraordinary Shareholders Meeting, Jul 15, 2014

Extrawell Pharmaceutical Holdings Ltd., Special/Extraordinary Shareholders Meeting, Jul 15, 2014., at 15:00 China Standard Time. Location: Monaco Room, Basement 1. Agenda: To consider execution of the disposal agreement entered into between Extrawell (BVI) Limited and Clear Rich International Limited.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
858:HK $0.38 HKD -0.005

858 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 858.
View Industry Companies
 

Industry Analysis

858

Industry Average

Valuation 858 Industry Range
Price/Earnings 56.3x
Price/Sales 6.0x
Price/Book 2.7x
Price/Cash Flow 57.1x
TEV/Sales 3.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact EXTRAWELL PHARMACEUTICAL, please visit www.extrawell.com.hk. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.